Cat. No. 3993
Alternative Name: Seocalcitol
Chemical Name: (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-
Biological ActivityVitamin D receptor (VDR) agonist; analog of calcitriol (Cat. No. 2551). Exhibits anti-tumor and anti-proliferative activity with reduced hypercalcemic effects. 60 times more potent in inhibiting MCF-7 cell growth in vitro; also shown to induce autophagy in MCF-7 cells. Reverses the effects of parathyroid hormone-related protein (PTHrP).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Abdaimi et al (1999) Reversal of hypercalcaemia with the vitamin D analogue EB1089 in a human model of squamous cancer. Cancer Res, 59 3325.
Hoyer-Hansen et al (2005) Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ. 12 1297. PMID: 15905882.
Lu et al (2008) Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. Mol.Cancer Ther. 7 1268. PMID: 18483314.
Ormerod et al (2008) The calcitriol analogue EB1089 impairs alveolarization and induces localized regions of increased fibroblast density in neonatal rat lung. Exp.Lung.Rs. 34 155.
Bhatia et al (2009) EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol.Cancer Ther. 8 1787. PMID: 19584236.
If you know of a relevant citation for this product please let us know.
Keywords: EB 1089, supplier, EB1089, VDR, agonist, Vitamin, D, receptors, seocalcitol, VDR-like
Find multiple products by catalog number
New Products in this Area
High affinity aryl hydrogen receptor (AhR) agonistML 179
Selective liver receptor homolog 1 (LRH1) inverse agonistAC 186
Potent and selective ERβ agonist; neuroprotectiveIsotretinoin
Endogenous agonist for retinoic acid receptors; inducer of neuronal differentiationBTC
Selective estrogen receptor modulator (SERM)
July 7 - 11, 2015
Rio de Janeiro, Brazil